Introduction

Suprax, the brand name for cefixime, is a third-generation cephalosporin antibiotic that has been widely used in clinical practice for over three decades. Developed in the 1980s, cefixime belongs to the beta-lactam class of antibiotics and exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. Unlike many earlier cephalosporins, it has an extended spectrum of activity against Gram-negative bacteria, including some strains resistant to older antibiotics. This report provides a concise yet thorough examination of Suprax, covering its pharmacology, clinical indications, dosage regimens, side effects, contraindications, drug interactions, and special considerations.

Pharmacology and Mechanism of Action

Cefixime acts by binding to penicillin-binding proteins (PBPs) located in the bacterial cell wall. This binding inhibits transpeptidases, enzymes necessary for cross-linking peptidoglycan chains, thereby disrupting cell wall integrity and leading to bacterial lysis. As a third-generation cephalosporin, cefixime has enhanced activity against Gram-negative organisms due to its increased affinity for PBPs and improved penetration through the outer membrane. It is stable against many beta-lactamases, though not against extended-spectrum beta-lactamases (ESBLs) or carbapenemases. Cefixime is bactericidal and time-dependent, meaning its efficacy is best correlated with the duration that serum concentrations remain above the minimum inhibitory concentration (MIC) for the pathogen.

Spectrum of Activity

Cefixime is primarily effective against:

  • Gram-negative bacteria: Haemophilus influenzae (including beta-lactamase-positive strains), Moraxella catarrhalis, Neisseria gonorrhoeae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and some Enterobacter species.
  • Gram-positive bacteria: Streptococcus pyogenes (group A streptococci), Streptococcus pneumoniae (though resistance is increasing), and some strains of Staphylococcus aureus (but not methicillin-resistant S. aureus – MRSA).

Notably, cefixime has little activity against Pseudomonas aeruginosa, Bacteroides fragilis, or enterococci.

Clinical Indications

Suprax is approved for the treatment of various infections, including:

  • Acute otitis media: Especially in children, caused by H. influenzae, M. catarrhalis, or S. pneumoniae.
  • Pharyngitis and tonsillitis: Caused by S. pyogenes.
  • Acute exacerbations of chronic bronchitis: (https://margheritabianchinipsicologa.it/images/products/vermox.webp) Due to H. influenzae, M. catarrhalis, or S. pneumoniae.
  • Uncomplicated urinary tract infections: Caused by E. coli or K. pneumoniae.
  • Uncomplicated gonorrhea: Cefixime is a recommended first-line treatment for uncomplicated genital or rectal gonorrhea, though increasing resistance has prompted combination therapy with azithromycin in some guidelines.
  • Acute uncomplicated cystitis in women.
  • Lyme disease (early stages, though not first-line).

Additionally, cefixime is sometimes used off-label for other infections, such as typhoid fever in areas with susceptibility.

Dosage and Administration

Suprax is available in oral formulations: tablets (200 mg, 400 mg), chewable tablets (100 mg, 200 mg), and oral suspension (100 mg/5 mL or 200 mg/5 mL). The typical adult dose for most infections is 400 mg once daily or 200 mg twice daily for 7–14 days. For uncomplicated gonorrhea, a single oral dose of 400 mg is recommended. Pediatric dosing is weight-based: 8 mg/kg/day (up to 400 mg) given once or twice daily. For acute otitis media in children, a 10-day course is typical. The oral suspension should be taken with food to minimize gastrointestinal upset, though absorption is not significantly affected. Dose adjustments are necessary in patients with severe renal impairment (creatinine clearance <30 mL/min); the usual recommendation is to reduce the dose by half or extend the dosing interval.

Side Effects

Suprax is generally well-tolerated. Common adverse effects include:

  • Gastrointestinal: diarrhea (most frequent), nausea, vomiting, dyspepsia, and abdominal pain. Diarrhea may be related to alterations in gut flora.
  • Hypersensitivity: rash, urticaria, pruritus, and rarely anaphylaxis. Cross-reactivity occurs in about 10% of patients with penicillin allergy.
  • Central nervous system: headache, dizziness, and rare cases of seizures (especially in renally impaired patients on high doses).
  • Hematologic: reversible eosinophilia, thrombocytopenia, and leukopenia.
  • Hepatobiliary: transient elevations in liver enzymes.
  • Renal: interstitial nephritis (rare).
  • Overgrowth of Clostridium difficile leading to pseudomembranous colitis, a potentially severe complication.

Serious adverse effects are uncommon but include Stevens-Johnson syndrome, toxic epidermal necrolysis, and serum sickness-like reactions.

Contraindications

Cefixime is contraindicated in patients with a known hypersensitivity to cephalosporins or any component of the formulation. Caution is advised in patients with a history of type I hypersensitivity reactions (anaphylaxis) to penicillins or other beta-lactams. It should also be avoided in patients with phenylketonuria due to the aspartame content in some chewable tablets and suspension preparations. Severe renal impairment requires dose adjustment; use in neonates is not recommended due to lack of safety data.

Drug Interactions

Cefixime can potentiate the effects of oral anticoagulants (e.g., warfarin) by reducing vitamin K production in the gut. Probenecid inhibits renal tubular secretion of cefixime, increasing its serum concentration. Antacids or H2-receptor antagonists may reduce absorption, though the effect is not clinically significant if spaced apart. Live bacterial vaccines (e.g., typhoid oral vaccine) may be less effective during cefixime therapy.

Special Populations

  • Pregnancy: Cefixime is classified as FDA Pregnancy Category B (animal studies show no risk, but no adequate human studies). It is generally considered safe during pregnancy when indicated.
  • Lactation: Small amounts are excreted in breast milk; caution is advised, but it is usually compatible with breastfeeding.
  • Pediatrics: Safe for children older than 6 months; safety in infants under 6 months has not been established.
  • Geriatrics: Age-related renal decline may necessitate dose adjustment.

Resistance

Resistance to cefixime is a growing concern, especially among N. gonorrhoeae (where cefixime minimal inhibitory concentrations have increased globally) and S. pneumoniae. Mechanisms of resistance include altered PBPs, beta-lactamase production (especially ESBLs), and efflux pumps. Susceptibility testing is recommended for serious infections.

Conclusion

Suprax (cefixime) remains a valuable oral antibiotic for a variety of commonly encountered bacterial infections, particularly those involving the respiratory tract, urinary tract, and uncomplicated gonorrhea. Its once- or twice-daily dosing and generally favorable safety profile contribute to its continued use. However, emerging resistance patterns, especially in gonococci and pneumococci, necessitate prudent prescribing and adherence to local susceptibility data. Clinicians should weigh the benefits against potential side effects and consider individual patient factors. Overall, cefixime is a well-established agent in the armamentarium against infectious diseases.